The membrane-anchored serine protease, matriptase, is consistently dysregulated in a range of human carcinomas, and high matriptase activity correlates with poor prognosis. Furthermore, matriptase is unique among tumor-associated proteases in that epithelial stem cell expression of the protease suffices to induce malignant transformation. Here, we use genetic epistasis analysis to identify proteinase-activated receptor (PAR)-2-dependent inflammatory signaling as an essential component of matriptasemediated oncogenesis. In cell-based assays, matriptase was a potent activator of PAR-2, and PAR-2 activation by matriptase caused robust induction of nuclear factor (NF)kB through Gai. Importantly, genetic elimination of PAR-2 from mice completely prevented matriptase-induced pre-malignant progression, including inflammatory cytokine production, inflammatory cell recruitment, epidermal hyperplasia and dermal fibrosis. Selective ablation of PAR-2 from bone marrow-derived cells did not prevent matriptasedriven pre-malignant progression, indicating that matriptase activates keratinocyte stem cell PAR-2 to elicit its pro-inflammatory and pro-tumorigenic effects. When combined with previous studies, our data suggest that dual induction of PAR-2-NFkB inflammatory signaling and PI3K-Akt-mTor survival/proliferative signaling underlies the transforming potential of matriptase and may contribute to pro-tumorigenic signaling in human epithelial carcinogenesis.
INTRODUCTION
Dysregulated pericellular proteolytic signaling is a major epigenetic driver of the sequential transformation of a normal human epithelial stem cell to a tumor cell (reviewed in Lopez-Otin and Hunter 1 ). In this regard, a wealth of evidence has coalesced within the past decade to implicate the aberrant expression and activity of the epithelial membrane-anchored serine protease, matriptase, to the genesis and progression of human epithelial cancers. Matriptase is almost ubiquitously expressedin the epithelial compartment of both pre-malignant and malignant human tissues, where its activity is derailed in a variety of manners that include overexpression, misexpression and loss of post-transcriptional regulation by cognate protease inhibitors [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] (reviewed in List 16 and Bugge et al. 17 ) For example, during multistage squamous cell carcinogenesis, matriptase expression undergoes a remarkable translocation from postmitotic suprabasal cells to proliferative cells of the basal compartment, including epithelial stem cells with tumorigenic potential. 13, 18 Importantly, we have previously shown that mimicking this translocation by misexpressing matriptase at low levels in the basal keratinocyte compartment suffices to induce malignant transformation and dramatically potentiates carcinogen-induced tumor formation in transgenic mice. 19 Proteinase-activated receptor (PAR)-2 is a G-protein-coupled receptor with pleiotropic functions in vertebrate development and in the maintenance of postnatal homeostasis. Dysregulated PAR-2 activation is believed to contribute to a vast number of common human diseases, owed in particular to the ability of the receptor to induce key inflammatory signaling pathways. [20] [21] [22] [23] PAR-2 was originally identified as a protease-activated receptor that was distinct from PAR-1 in that it responded poorly to thrombin but was efficiently activated by the digestive enzyme trypsin. 24 Subsequently, a large number of trypsin-like serine proteases were shown to be able to activate PAR-2 in various cell-based assays. These include coagulation factors FVIIa and FXa, facilitated by FVIIa binding to the tissue factor, [25] [26] [27] mast cell alpha and beta tryptases, kallikreins 4, 5, 6 and 14, [28] [29] [30] as well as the membraneanchored serine proteases, human airway trypsin-like serine protease, 31 TMPRSS2, 32 prostasin, 21 hepsin 21 and matriptase. 33 Despite the profusion of proteases displaying the capacity to activate PAR-2 ex vivo, the specific protease or repertoire of proteases that activates the receptor in many physiological and pathological contexts in vivo remains to be established. PAR-2 is expressed by both primary keratinocytes and established keratinocyte cell lines, 34, 35 where its activation can elicit a range of cellular responses. These include inositol phospholipid hydrolysis and calcium mobilization, 34 activation of c-Jun N-terminal kinase, p38 mitogen-activated protein kinase and Rho, 36, 37 induction of nuclear factor (NF)kB activity, 37 secretion of 1 inflammatory cytokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-6, 38 interleukin-8/ CXCL1/Gro-1 35 and thymic stromal lymphopoietin, 39 as well as release of prostaglandins E 2 and F 2a 40 and expression of intercellular cell adhesion molecule-1. 41 In this study, we determined the specific contribution of PAR-2 to the oncogenic activity of matriptase, because matriptaseinduced squamous cell carcinogenesis is preceded by a signature chronic inflammation and also because the protease and the G-protein-coupled receptor are coexpressed in normal squamous epithelium and in squamous cell carcinoma. 15, 19, 42 We took advantage of the fact that PAR-2 deficiency in mice causes partial embryonic lethality, but that the born offspring is healthy and displays a normal long-term survival, thus enabling the use of a definitive genetic epistasis analysis to address this issue. 21, 43 Importantly, we show that both matriptase-driven premalignant progression and the potentiation of carcinogeninduced squamous cell carcinogenesis by matriptase are entirely dependent on nonhematopoietic PAR-2. Furthermore, we show that matriptase activation of PAR-2 leads to pro-tumorigenic inflammatory cytokine release via activation of NFkB through Gai. The study identifies matriptase as a candidate in vivo activator of PAR-2 in the context of human tumorigenesis and demonstrates the importance of post-transcriptional deregulation of PAR-2 signaling to epithelial malignant transformation.
RESULTS
Loss of PAR-2 prevents matriptase-induced pre-malignant progression of mouse squamous epithelium Matriptase is exclusively expressed in the suprabasal compartment of homeostatic mouse epidermis, but the protease is expressed in the stem cell compartment upon exposure to tumorpromoting agents. 13, 18 Mimicking this translocation of matriptase expression by low-level expression of a mouse matriptase cDNA under the control of a keratin-5 promoter in transgenic mice (hereafter termed K5-Mat þ /0 mice) leads to spontaneous multistage squamous cell carcinogenesis with tumor formation beginning at 1 year of age. 19 PAR-2 is expressed in the keratinocyte compartment and has been hypothesized to be an important mediator of skin inflammation following its activation by trypsin-like serine proteases (see Introduction). Therefore, to determine the possible contribution of PAR-2 to matriptasemediated squamous cell carcinogenesis, we interbred K5-Mat
À / À and wild-type mice. The outward appearance and health of the mice were followed for 52 weeks, after which the mice were euthanized for histological examination. As reported previously, K5-Mat þ /0 mice at this age presented with alopecia secondary to follicular metaplasia and ichthyosis ( Figure 1a , left panel and data not shown), epidermal hyperplasia ( Figure 1b ) and hyperproliferation (Figure 1c ), multifocal dysplasia ( Figure 1d , example with arrowhead), and expression of the stressassociated marker, keratin-6, in the interfollicular epidermis ( Figure 1h ). As also reported previously, dermal fibrosis with increased dermal cellularity was prominent (Figure 1l ). Unexpectedly, however, even at this advanced age, K5-Mat þ /0 ;F2rl1 Matriptase fails to potentiate chemical carcinogenesis in the absence of PAR-2 In addition to initiating spontaneous malignant progression, dysregulated matriptase potentiates ras-dependent squamous cell carcinogenesis induced by topical application of the carcinogen 7,12-dimethylbenzanthracene (DMBA). 19 To establish the contribution of PAR-2 to matriptase-mediated potentiation of chemically induced squamous cell carcinogenesis, we exposed K5-Mat
À / À mice and their associated K5-Mat Nonhematopoietic cell-derived PAR-2 mediates matriptase-driven pre-malignant progression PAR-2 is expressed not only by keratinocytes but also by a variety of leukocyte populations that infiltrate the skin during preneoplastic progression. We therefore next examined if the failure of PAR-2-deficient mice to promote the stereotypic protumorigenic proliferative responses that are associated with dysregulated epidermal matriptase were caused by loss of keratinocyte matriptase-PAR-2 signaling or, rather, were an indirect consequence of the intrinsic defects of PAR-2-deficient leukocytes. For this purpose, we performed bone marrow chimeric studies in which K5-Mat þ /0 and wild-type littermate mice were lethally irradiated and thereafter reconstituted with histocompatible bone marrow from either F2rl1 þ / þ or F2rl1 À / À mice. Successful bone marrow transplantation was ensured by FACS analysis for expression of donor-specific hematopoietic markers (Supplementary Figure 1) . After recovery from grafting, the bone marrow chimeric mice were followed for 11 weeks then killed and examined ( Figure 3 ). As predicted, K5-Mat þ /0 mice grafted with wild-type bone marrow displayed epidermal hyperplasia, epidermal hyperproliferation and dermal fibrosis when compared with wild-type mice grafted with wild-type bone marrow (Figures 3a and b, compare the example in c with that in e, and the example in g with that in i). No diminution of hyperplasia, hyperproliferation and fibrosis was apparent when K5-Mat þ /0 mice were grafted with PAR-2-deficient bone marrow (Figures 3a and b , compare the example in d with that in f, and the example in h with that in j). Thus, epithelial hyperplasia, hyperproliferation and dermal collagen density were all similar in K5-Mat þ /0 mice grafted with either PAR-2-deficient or PAR-2-sufficient bone marrow. These data demonstrate that dysregulated matriptase activates PAR-2 on cells of non-hematopoietic origin to elicit its tumor-promoting effects.
Dysregulated matriptase fails to elicit dermal inflammatory cell recruitment in the absence of PAR-2 Matriptase-induced pre-malignant progression is associated with a signature accumulation of inflammatory cells in the dermis. 13, 19 To explore if dysregulated matriptase induces inflammatory cell recruitment through PAR-2, we enumerated dermal mast cells in young (8-10-week-old) littermate and older (52-week-old) littermate K5-Mat 
(N ¼ 7, green circles), wild-type (N ¼ 5, red circles) and F2rl1 À / À mice (N ¼ 6, grey circles) at 52 weeks of age. ***Po0.0006 (Mann-Whitney U-test, two-tailed). NS ¼ not significant (c). Epidermal keratinocyte proliferation rates in littermate K5-Mat ;F2rl1 À / À mice being similar to that in wild-type and F2rl1
À / À littermates (compare the example in Figure 4b with that in c and d, i and Figure 4f with g and h, j). These data suggest that dysregulated matriptase mediates inflammatory cell recruitment through PAR-2.
Dysregulated matriptase induces inflammatory cytokine release through PAR-2 We next explored if the dramatic impact of global PAR-2 ablation on matriptase-driven pre-malignant progression could be related to the elimination of a keratinocyte-intrinsic matriptase-PAR-2-mediated inflammatory signaling pathway. For this purpose, we performed qPCR analysis of skin cells to determine the mRNA levels of a number of keratinocyte-produced inflammatory cytokines and inflammatory mediators in young (8-10-week-old) K5-Mat
À / À mice and their associated K5-Mat
À / À and wild-type littermates. These included mRNAs encoding the murine interleukin-8 equivalent, chemokine (C-X-C motif) ligand 1 (Cxcl1), interleukin-1b (Il1b), thymic stromal lymphopoietin (Tslp), colony stimulating factor 2 (Csf2), tumor necrosis factor (Tnf), interferon-g (Ifng), and intercellular adhesion molecule 1 (Icam1) (Figures 5a-g ). mRNA levels of Cxcl1, Il1b, Tslp, Csf2, Tnf and Icam1 were all significantly increased (2-171-fold) in young K5-Mat þ /0 mice when compared with their wild-type 
, grey triangles) mice. The mice were treated with DMBA every 3 weeks and were followed for up to 63 weeks. ***Po0.0001, K5-Mat þ /0 ;F2rl1 þ / þ versus other genotypes in a (log-rank test, two-tailed). Vertical and horizontal bars in b indicate standard error of the mean. (c-f ) Representative outward appearance of littermate K5-Mat littermates (Figures 5a-e and g ), and Ifng mRNA displayed a 3.6-fold increase without reaching statistical significance (Figure 5f ). This result demonstrates that dysregulated matriptase induces expression of skin inflammatory mediators. Importantly, loss of PAR-2 from K5-Mat þ /0 mice reduced the level of expression of Cxcl1, Il1b, Tslp, Csf2 and Tnf mRNA species to levels similar to those observed in wild-type and F2rl1 À / À mice (Figures 5a-e) , suggesting that keratinocyte PAR-2 is required for matriptaseinduced expression of these cytokines. To substantiate this hypothesis, we next measured mRNA levels of Cxcl1, Il1b, Tslp, Csf2, Tnf, Ifng and Icam1 in 17-week-old K5-Mat þ /0 mice reconstituted with PAR-2-deficient and -sufficient bone marrow, respectively (Figures 5h-n) . As expected, mRNA levels of Cxcl1, Il1b, Tslp, Tnf, Ifng and Icam1 (Figures 5h-j, l-n) were all significantly increased in K5-Mat þ /0 mice reconstituted with wild-type bone marrow when compared with control mice (wild-type mice reconstituted with either wild-type or PAR-2-deficient bone marrow), whereas Csf2 mRNA was 1.7-fold increased without reaching statistical significance (Figure 5k) . Il1b, Tslp, Tnf, Ifng and Icam mRNA levels remained significantly increased in K5-Mat þ /0 mice reconstituted with PAR-2-deficient bone marrow (Figures 5i, j, l, m and n) , whereas Cxcl1 and Csf2 mRNA were, respectively, 1.8-and 1.7-fold increased (Figures 5h  and k) without reaching statistical significance, showing that hematopoietic PAR-2 is dispensable for the induction of expression of skin inflammatory mediators by dysregulated matriptase through PAR-2. Analysis of skin from 52-week-old mice showed a significant increase in Cxcl1, Il1b, Tslp and Csf2 mRNA levels of K5-Mat þ /0 mice when compared with wild-type littermates (Figures 5o-r) . The levels of these four cytokine mRNA species were reduced 24-, 8-, 35-and 47-fold, respectively, by PAR-2 elimination, reaching significance for Cxcl1, while not reaching significance for Il1b, Tslp and Csf2 (Po0.13, 0.065 and 0.070, respectively). Taken together, the data indicate that dysregulated matriptase induces early expression of key protumorigenic inflammatory mediators through keratinocyte PAR-2.
Matriptase activates NFkB through PAR-2 and Gai As NFkB is a key epidermal regulator of inflammatory cytokine production in both non-neoplastic and neoplastic contexts 44, 45 and because many of the cytokines whose mRNAs were increased in K5-Mat þ /0 mice are regulated by NFkB, we investigated if matriptase activation of PAR-2 could induce NFkB activity in epithelial cells. For this purpose, we used a recently established reconstituted cell-based assay 46, 47 in which HEK293 cells were transfected with a PAR-2 expression vector and either a serumresponse element (SRE) -luciferase reporter plasmid or NFkBluciferase reporter plasmid. The transfected cells were then exposed to a PAR-2 agonist, a dual PAR-1 and PAR-2 agonist or 
red circles), and F2rl1
À / À mice (N ¼ 6-7, grey circles). *Po0.01, **Po0.001, NS ¼ not significant (Mann-Whitney U-test, two-tailed).
only a minor effect on the ability of activated PAR-2 to induce SRE activity (Figure 6j ). Taken together, these data demonstrate that matriptase-activated PAR-2 selectively signals through Gai to activate NFkB. We recently identified pro-HGF activation as a critical mechanism by which dysregulated matriptase promotes squamous cell carcinogenesis, based on the failure of matriptase to accelerate tumor progression in mice with specific ablation of the HGF receptor, c-Met, from the keratinocyte stem cell compartment. 13 Interestingly, however, unlike PAR-2 ablation, loss of c-Met failed to prevent mast cell accumulation in response to dysregulated matriptase, with the number of mast cells being similar in c-Met-sufficient K5-Mat þ /0 and c-Met-deficient K5-Mat þ /0 mice (Supplementary Figures 3 A-D) . Furthermore, activation of PAR-2 by treating cells with soluble recombinant matriptase for up to 3 h failed to induce transactivation of c-Met, as evidenced by the absence of autophosphorylation of c-Met and phosphorylation of Gab-1 (Supplementary Figure 3E and F) . These data indicate that activation of PAR-2 and c-Met by matriptase induces separate protumorigenic signaling pathways and that each is required for the promotion of squamous cell carcinogenesis by the membraneanchored serine protease.
DISCUSSION
Multiple studies have linked dysregulated matriptase to human epithelial carcinogenesis, but the molecular mechanisms by which the membrane protease promotes carcinogenesis are only beginning to be elucidated. Here we employed genetic epistasis analysis to specifically query the contribution of one candidate substrate, PAR-2, to matriptase-driven squamous cell carcinogenesis. Unexpectedly, we found that genetically eliminating PAR-2 sufficed to negate all pro-tumorigenic effects of dysregulated epidermal matriptase. Thus, matriptase-driven pre-malignant progression did not occur in the absence of PAR-2, and dysregulated matriptase failed to potentiate DMBA-induced carcinogenesis in the absence of the G-protein-coupled receptor. Specific ablation of PAR-2 from hematopoietic cells did not affect matriptase-mediated pre-malignant progression, suggesting that dysregulated matriptase activates epidermal (most likely 
red circles) and F2rl1
À / À mice (N ¼ 3-5, grey circles). *Po0.01, **Po0.001, N.S. ¼ not significant (Mann-Whitney U-test, two-tailed).
keratinocyte) PAR-2 to promote malignant progression. Because matriptase and PAR-2 have been shown to be consistently coexpressed in the epithelial compartment of human squamous cell carcinoma, 15 the current study provides strong evidence that a matriptase-PAR-2 signaling axis contributes to human squamous cell carcinogenesis.
We have previously shown that matriptase-driven squamous cell carcinogenesis is preceded by a conspicuous recruitment of large numbers of mast cells to the underlying dermis. 19 The current study provides evidence that this effect of matriptase dysregulation is related to PAR-2-dependent NFkB activation via Gai and the associated release of NFkB-dependent inflammatory cytokines. First, the matriptase-mediated increase in the mRNA levels of several NFkB-induced inflammatory cytokines was entirely dependent on non-hematopoietic PAR-2. Second, in a reconstituted cell-based system, matriptase activation of PAR-2 induced a robust activation of an NFkB reporter gene via Gai. Because the causal association between chronic inflammation and epithelial carcinogenesis is well established, it is possible that the elicitation of pro-inflammatory cytokines via NFkB activation could account for all the pro-tumorigenic effects associated with untimely activation of PAR-2 by matriptase. The current study, however, does not exclude other PAR-2 activation-induced effects, such as the direct stimulation of proliferation, cell death protection or motility enhancement. Our findings are aligned with a previous study showing that soluble matriptase can induce cytokine release in cultured human endothelial cells through PAR-2 and NFkB. 48 By using a genetic epistasis approach similar to the current study, we have previously shown that dysregulated matriptase promotes squamous cell carcinogenesis by activating a c-Met-Akt signaling pathway by proteolytic conversion of pro-HGF to active HGF on the keratinocyte cell surface. 13 Interestingly, in this study, imposition of either PAR-2 or c-Met deficiency on K5-Mat þ /0 transgenic mice negated the ability of dysregulated matriptase to potentiate DMBA-induced tumorigenesis and blocked matriptase-driven pre-malignant progression, including epidermal hyperproliferation, dysplasia, follicular metaplasia, expression of stress-associated epidermal keratins and induction of dermal fibrosis. Analysis of archived tissues from c-Met- sufficient K5-Mat þ /0 and c-Met-deficient K5-Mat þ /0 mice did, however, reveal that loss of c-Met signaling, unlike loss of PAR-2 signaling, failed to prevent matriptase-induced inflammatory cell recruitment. Furthermore, although PAR-2 has been proposed to transactivate c-Met in the context of hepatocellular carcinoma invasion, 49 we found no evidence that PAR-2 activation was associated with increased c-Met activity using a reconstituted cellbased assay using HEK cells or using immortalized keratinocytes. An intriguing unanswered question that arises from these studies, therefore, is why matriptase-induced inflammatory PAR-2 signaling does not promote malignant progression in the absence of activated c-Met and, conversely, why matriptaseinduced c-Met-Akt signaling does not promote malignant progression in the absence of activated PAR-2.
In summary, by performing genetic epistasis analysis in an animal model, in which the signature dysregulation of matriptase in human carcinomas is mimicked by low-level misexpression of matriptase in the epidermis, 19 we have provided definitive evidence that matriptase proteolytically cleaves both PAR-2 and pro-HGF in vivo to activate tumor-promoting G-protein-coupled and receptor tyrosine kinase signaling pathways, respectively. Furthermore, we have shown that both pathways must be activated simultaneously by matriptase for the protease to exert its tumor-promoting effects on squamous epithelium. The study underscores that pericellular serine proteases may be excellent therapeutic targets for the prevention and treatment of cancer, owing to their convenient extracellular location and their capacity to regulate fundamental pro-tumorigenic cellular signaling pathways.
MATERIALS AND METHODS Animals
All experiments were performed in the Association for Assessment and Accreditation of Laboratory Animal Care International-Accredited Vivarium following institutional guidelines and standard operating procedures. The generation of mice overexpressing matriptase under the keratin-5 promoter (K5-Mat þ /0 ) has been reported previously. 19 Mice carrying a F2rl1 null allele 50 were purchased from the Jackson Laboratories (Bar Harbor, ME, USA). K5-Mat
þ / À and F2rl1 À / À mice in a mixed (FVB/NJ/ C57BL/6 J/Black Swiss) background were generated by interbreeding. The study was strictly littermate controlled to avoid genetic background differences from confounding data interpretation.
Chemical carcinogenesis
DMBA was diluted to a final concentration of 250 mg/ml in acetone and 100 ml was applied to the dorsal skin of the mice every 3 weeks.
Bone marrow chimeras
Bone marrow was isolated from either C57BL/6J-F2rl1 þ / þ mice or C57BL/ 6J-F2rl1 À / À mice and was injected intravenously into lethally irradiated (900 rads) 6-week-old K5-Mat þ /0 and wild-type littermate control F1 offspring from FVB/NJ-K5-Mat þ /0 mice crossed to C57BL/6 J mice. DMBA treatment was performed 8 weeks after transplantation as described above.
Histological and immunohistochemical analysis
Skin and tumor tissues were fixed for 24 h in 4% paraformaldehyde in phosphate-buffered saline, processed in paraffin, sectioned into sagittal 3-mm sections and stained with hematoxylin and eosin, Masson's trichrome or toluidine blue prior to histopathological assessment. Immunohistochemical analysis was performed as described previously. 51 Antibody recognizing keratin-6 (Covance, Chantilly, VA, USA) was used for staining. Epithelial cell proliferation was visualized by intraperitoneal injection of 10 mg/g of 5-bromo-2 0 -deoxyuridine, 2 h prior to euthanasia. 5-Bromo-2 0 -deoxyuridine incorporation was detected with a mouse anti-BrdU antibody (Accurate, Westbury, NY, USA). Bound antibodies were visualized with the Vectastain ABC peroxidase kit as recommended by the manufacturer (Vector Laboratories, Burlingame, CA, USA) and developed with the addition of the 3,3 0 -diaminobenzidine substrate (Sigma, St Louis, MO, USA). Slides were digitalized using a ScanScope (Aperio, Vista, CA, USA) and the height of the epidermis (epithelial thickness), mast cell count per 10 5 mm 2 and the number of 5-bromo-2 0 -deoxyuridine-positive basal cells (basal proliferation rates) were quantified.
RNA preparation and real-time PCR
Whole skin was snap-frozen in liquid nitrogen and ground to a fine powder with a mortar and pestle. Total RNA was prepared by extraction in Trizol reagent (Life Technologies, Frederick, MD, USA) as recommended by the manufacturer. Reverse transcription and PCR amplification were performed using the RETROscript Kit (Ambion, Austin, TX, USA), as recommended by the manufacturer. First-strand cDNA synthesis was performed using an Oligo dT primer. The following primer pairs were used for qPCR: Tnf, 
PAR-2 activation assay
The assay was performed as described before. 46 Briefly, HEK293 cells were plated on poly-L-lysine-coated 24-well plates and grown in Dulbecco's Modified Eagle Medium (Life Technologies) supplemented with 10% fetal bovine serum for 24 h. Cells were cotransfected either with pSRE-firefly luciferase (50 ng) (Stratagene, Cedar Creek, TX, USA) or with NFkB-firefly luciferase (50 ng) reporter (Stratagene, La Jolla, CA, USA), combined with pRL-Renilla luciferase (20 ng), pcDNA 3.1-PAR-2 (50 ng) or pcDNA 3.1-PAR-1 (50 ng) (Missouri S&T cDNA Resource Center, Rolla, MO, USA) using Lipofectamine according to the manufacturer's instructions (Life Technologies). The medium was changed after 12 h, and 36 h after transfection the cells were serum-starved overnight and then stimulated with matriptase (R&D, Minneapolis, MN, USA), PAR-2 agonist peptide ((3H)2-furoyl-LIGRL-NH2) (Tocris, Minneapolis, MN, USA), PAR-1 and -2 agonist peptide (tcY-NH2) (Tocris) or vehicle for 6 h. Cells were washed twice in phosphate-buffered saline and luciferase activity was determined using the dual luciferase assay kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Luminescence was measured using a Microtiter plate luminometer (Dynex Technologies, Chantilly, VA, USA) and SRE activation was determined as the ratio of firefly to Renilla luciferase counts.
G-protein assay
HEK293T cells were plated in 24-well plates and transfected with either SRE-luciferase or NFkB-luciferase reporter together with pRL-Renilla and PAR-2. Thirty-six hours after transfection, the cells were serum-starved overnight with pertussis toxin (50 ng/ml) or with vehicle added to the media in a final concentration. For all the three above-mentioned G-protein experiments, the cells were stimulated with 10 mM PAR-2 agonist or 15 nM recombinant human matriptase for 6 h at 37 1C before the luciferase activity was determined.
